<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079634</url>
  </required_header>
  <id_info>
    <org_study_id>STU00209610</org_study_id>
    <nct_id>NCT04079634</nct_id>
  </id_info>
  <brief_title>Esophageal Temperature Management During Cryo AF Ablation (EnsoETM)</brief_title>
  <acronym>EnsoETM</acronym>
  <official_title>Esophageal Temperature Management During Cryo AF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Attune Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine if esophageal warming using the Attune&#xD;
      Medical Esophageal Heat Transfer Device (EnsoETM) limits the frequency or severity of thermal&#xD;
      injury during cryoballoon ablation of atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter ablation of atrial fibrillation (AF) has become a common ablation procedure&#xD;
      performed worldwide. The cornerstone of this procedure is pulmonary vein isolation (PVI). PVI&#xD;
      can be achieved by multiple methods, the two most common being radiofrequency (RF) and&#xD;
      cryoablation. Energy delivery may extend beyond the atrial myocardium and result in damage to&#xD;
      adjacent structures, including the esophagus. Atrio-esophageal fistula (AEF) is a rare, but a&#xD;
      well-recognized complication of percutaneous AF ablation. The occurrence rate of esophageal&#xD;
      injury has varied depending on the reporting center, timing of endoscopy, and the ablation&#xD;
      technique utilized. Esophageal ulceration is likely the initial injury that leads to AEF&#xD;
      formation and is probably present within hours to days of the ablation procedure.&#xD;
&#xD;
      The Attune Medical Esophageal Heat Transfer Device (EnsoETM) is a non-sterile, multi-lumen&#xD;
      silicone tube placed in the esophagus for the purpose of cooling or warming a patient while&#xD;
      simultaneously allowing gastric decompression and drainage. For this study, the EnsoETM tube&#xD;
      will be used during cardiac ablation procedures for the intended indication of patient&#xD;
      temperature management using approved settings/parameters as detailed in the product&#xD;
      instructions for use document. EnsoETM is an FDA approved device.&#xD;
&#xD;
      This prospective, randomized study will include 40 patients with symptomatic AF undergoing&#xD;
      index PVI under general anesthesia at Northwestern Memorial Hospital. Patients will be&#xD;
      randomized in a 1:1 fashion with 20 patients (Group A) randomized to undergo the ablation&#xD;
      procedure with esophageal warming and the other 20 patients (Group B) will serve as the&#xD;
      control group and will not have the EnsoETM device used. All patients will undergo&#xD;
      esophagogastroduodenoscopy (EGD) 1-2 days following the ablation procedure to evaluate for&#xD;
      esophageal injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will not be informed if they were randomized to control or treatment until Month 2 follow-up visit.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence rate of esophageal thermal injury between groups</measure>
    <time_frame>Post-Procedure Day 1</time_frame>
    <description>Endoscopic evaluation of esophagus</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placement of study device (EnsoETM) for temperature management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placement of standard temperature probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Esophageal warming</intervention_name>
    <description>Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Standard temperature probe monitoring</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients above the age of 18 years old.&#xD;
&#xD;
          2. Patients with the diagnosis of atrial fibrillation undergoing clinically indicated&#xD;
             de-novo AF ablation procedure.&#xD;
&#xD;
          3. Patients must be willing to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with contraindication to EGD.&#xD;
&#xD;
          2. History of prior AF ablation procedures.&#xD;
&#xD;
          3. Significant co-morbidities that preclude standard ablation procedure.&#xD;
&#xD;
          4. Patient is ineligible for EnsoETM placement due to:&#xD;
&#xD;
               -  Known esophageal deformity or evidence of esophageal trauma (for example history&#xD;
                  of esophagectomy, previous swallowing disorders, achalasia).&#xD;
&#xD;
               -  Known ingestion of acidic or caustic poisons within the prior 24 hours.&#xD;
&#xD;
               -  Patients with &lt;40 kg of body mass.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nishant Verma, MD</last_name>
    <phone>312-926-9541</phone>
    <email>Nishant.Verma@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Huskin, RN</last_name>
    <phone>312-695-4067</phone>
    <email>anna.huskin@nm.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Carswell</last_name>
      <phone>312-926-7554</phone>
      <email>amy.carswell@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Huskin</last_name>
      <phone>312-695-4067</phone>
      <email>Anna.huskin@nm.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Nishant Verma</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within one year of enrollment closure</ipd_time_frame>
    <ipd_access_criteria>Consent will be posted to ClinicalTrials.Gov</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

